TRH   Click here for help

GtoPdb Ligand ID: 2139

Synonyms: thyroliberin
Approved drug
TRH is an approved drug (FDA (1976))
Compound class: Endogenous peptide in human, mouse or rat
Comment: This structure matches the structure deposited with the INN record for protirelin, which is synthetic TRH.
Species: Human, Mouse, Rat
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: trh

TRH is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES O=C1CCC(N1)C(=O)NC(C(=O)N1CCCC1C(=O)N)Cc1nc[nH]c1
Isomeric SMILES O=C1CC[C@H](N1)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N)Cc1nc[nH]c1
InChI InChI=1S/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h7-8,10-12H,1-6H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12-/m0/s1
InChI Key XNSAINXGIQZQOO-SRVKXCTJSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Chen D, Chen Q, Qin X, Tong P, Peng L, Zhang T, Xia C. (2023)
Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease.
Front Aging Neurosci, 15: 1209863. [PMID:37600512]
2. Coimbra JR, Sobral PJ, Santos AE, Moreira PI, Salvador JA. (2019)
An overview of glutaminyl cyclase inhibitors for Alzheimer's disease.
Future Med Chem, 11 (24): 3179-3194. [PMID:31838899]
3. Coimbra JRM, Moreira PI, Santos AE, Salvador JAR. (2023)
Therapeutic potential of glutaminyl cyclases: Current status and emerging trends.
Drug Discov Today, 28 (10): 103644. [PMID:37244566]
4. Gershengorn MC, Osman R. (1996)
Molecular and cellular biology of thyrotropin-releasing hormone receptors.
Physiol Rev, 76 (1): 175-91. [PMID:8592728]
5. Kehlen A, Haegele M, Böhme L, Cynis H, Hoffmann T, Demuth HU. (2017)
N-terminal pyroglutamate formation in CX3CL1 is essential for its full biologic activity.
Biosci Rep, 37 (4). [PMID:28739588]
6. Urayama A, Yamada S, Kimura R, Zhang J, Watanabe Y. (2002)
Neuroprotective effect and brain receptor binding of taltirelin, a novel thyrotropin-releasing hormone (TRH) analogue, in transient forebrain ischemia of C57BL/6J mice.
Life Sci, 72 (4-5): 601-7. [PMID:12467901]
7. Van Manh N, Hoang VH, Ngo VTH, Ann J, Jang TH, Ha JH, Song JY, Ha HJ, Kim H, Kim YH et al.. (2021)
Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design.
Eur J Med Chem, 226: 113819. [PMID:34536669]
8. Zhang Y, Wang Y, Zhao Z, Peng W, Wang P, Xu X, Zhao C. (2022)
Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases.
Eur J Pharmacol, 931: 175178. [PMID:35948163]